In contrast, in prostate cancer staging, prostate-specific membrane antigen PET/CT cutoff values correlate well with cancer aggressiveness and are widely used in clinical practice.13 Hence, further research is needed to establish standardized criteria and protocols for interpreting FDG-PET/CT findings in BC staging. This evidence concerns the gene FOLH1 and Familial prostate cancer.